Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

115.96 -0.91 (-0.78%)
Delayed Quote Updated: 11:50 AM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Insiders Buy Around $112M Of 3 Stocks ↗
US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Oncolytics Announced Updates On Clinical Trials Of New Treatment For Triple-Negative Metastatic Breast Cancer ↗
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Expert Ratings For Incyte ↗
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022 ↗
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment... 
Via Benzinga
News headline image
Why Are Incyte Shares Trading Lower Today? ↗
Incyte Corporation's (NASDAQ: INCY)  
Via Benzinga
News headline image
Recap: Incyte Q4 Earnings ↗
  Incyte (NASDAQ:INCY) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
News headline image
Bear Market Bets In Biotech ↗
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema ↗
Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to  
Via Benzinga
News headline image
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus ↗
Incyte Corporation (NASDAQ: INCY) is  
Via Benzinga
News headline image
Earnings Scheduled For February 8, 2022 ↗
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
News headline image
Incyte Provides Update on Parsaclisib and MCLA-145
From Incyte
Via Business Wire
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s... 
Via FinancialNewsMedia
News headline image
Where Incyte Stands With Analysts ↗
Within the last quarter, Incyte (NASDAQ:INCY) has observed the following an... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 ↗
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE: 
Via Benzinga
News headline image
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
From Incyte
Via Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer... 
Via FinancialNewsMedia
Topics Death
News headline image
This Biotech Is Working With Pfizer, Merck KGaA, Roche, and Other Leaders To Develop a Better Standard of Care for Breast Cancer ↗
Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cancer is the... 
Via Benzinga
News headline image
Cramer Shares His Thoughts On Incyte, Corning And More ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Incyte Corporation (NASDAQ: 
Via Benzinga
News headline image
4 Stocks Insiders Are Buying ↗
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
News headline image
Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder ↗
The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) supplemental marketing application seeking approval for ruxolitinib cream 1.5% (Opzelura), a... 
Via Benzinga
News headline image
Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Why Are Datadog, Zscaler, Airbnb, Fortinet, Lucid Trading Higher Premarket? ↗
Airbnb, Inc (NASDAQ: ABNB), Fortinet, Inc (NASDAQ: FTNT), Palo Alto Networks, Inc (NASDAQ: PANW), Lucid Group, Inc (NASDAQ: LCID), Zscaler, Inc (NASDAQ: ZS), and Datadog, Inc (... 
Via Benzinga
News headline image
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
News headline image
Annual Changes To The Nasdaq-100 Index ↗
The reconstituted Nasdaq index for 2022 (effective Dec. 20, 2021) has six new members; they replace FOX, TCOM, INCY, CDW, CERN, and CHKP. 
Via Talk Markets
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.